NCT00374101

Brief Summary

High intravenous dosage of Proton Pump Inhibitors is not better than standard dosage in bleeding peptic ulcers successfully treated by endoscopic therapy

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
450

participants targeted

Target at P50-P75 for phase_3

Timeline
Completed

Started Jan 2005

Geographic Reach
1 country

10 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2005

Completed
1.7 years until next milestone

First Submitted

Initial submission to the registry

September 7, 2006

Completed
1 day until next milestone

First Posted

Study publicly available on registry

September 8, 2006

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2007

Completed
Last Updated

April 5, 2007

Status Verified

April 1, 2007

First QC Date

September 7, 2006

Last Update Submit

April 4, 2007

Conditions

Keywords

PPIs,endoscopic therapy,peptic ulcers,upper gastrointestinal bleeding,non-variceal upper gastrointestinal bleeding

Outcome Measures

Primary Outcomes (1)

  • Rebleeding rates and surgical needs

Interventions

Eligibility Criteria

Age18 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Consecutive patients admitted for upper gastrointestinal bleeding secondary to peptic ulcers that have been successfully treated with endoscopic therapy

You may not qualify if:

  • Variceal esophageal bleeding
  • Concurrent PPI use
  • Moribund patients

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (10)

Division of Internal Medicine

Polla, Salerno, Italy

Location

Division of Gastroenterology

Caserta, Italy

Location

DIvision of Gastroenterology

Como, Italy

Location

Division of Gastroenterology

Cosenza, Italy

Location

DIvision of Internal Medicine

Ivrea, Italy

Location

Division of Gastroenterology

Piacenza, Italy

Location

Division of Gastroenterology

San Giovanni Rotondo, Italy

Location

Division of Gastroenterology

Torino, Italy

Location

Division of Gastroenterology

Treviso, Italy

Location

Division of Gastroenterology

Vasto, Italy

Location

Related Publications (2)

  • Andriulli A, Annese V, Caruso N, Pilotto A, Accadia L, Niro AG, Quitadamo M, Merla A, Fiorella S, Leandro G. Proton-pump inhibitors and outcome of endoscopic hemostasis in bleeding peptic ulcers: a series of meta-analyses. Am J Gastroenterol. 2005 Jan;100(1):207-19. doi: 10.1111/j.1572-0241.2005.40636.x.

    PMID: 15654802BACKGROUND
  • Andriulli A, Loperfido S, Focareta R, Leo P, Fornari F, Garripoli A, Tonti P, Peyre S, Spadaccini A, Marmo R, Merla A, Caroli A, Forte GB, Belmonte A, Aragona G, Imperiali G, Forte F, Monica F, Caruso N, Perri F. High- versus low-dose proton pump inhibitors after endoscopic hemostasis in patients with peptic ulcer bleeding: a multicentre, randomized study. Am J Gastroenterol. 2008 Dec;103(12):3011-8. doi: 10.1111/j.1572-0241.2008.02149.x.

MeSH Terms

Conditions

Peptic UlcerGastrointestinal Hemorrhage

Interventions

OmeprazolePantoprazole

Condition Hierarchy (Ancestors)

Duodenal DiseasesIntestinal DiseasesGastrointestinal DiseasesDigestive System DiseasesStomach DiseasesHemorrhagePathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

2-PyridinylmethylsulfinylbenzimidazolesSulfoxidesSulfur CompoundsOrganic ChemicalsPyridinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsBenzimidazolesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-Ring

Study Officials

  • Andriulli Angelo, MD

    Division of Gastroenterology, "Casa Sollievo della Sofferenza", San Giovanni Rotondo, ITALY

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
DOUBLE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

September 7, 2006

First Posted

September 8, 2006

Study Start

January 1, 2005

Study Completion

March 1, 2007

Last Updated

April 5, 2007

Record last verified: 2007-04

Locations